Literature DB >> 9831551

Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.

H Huang1, R Chopra, G L Verdine, S C Harrison.   

Abstract

A combinatorial disulfide cross-linking strategy was used to prepare a stalled complex of human immunodeficiency virus-type 1 (HIV-1) reverse transcriptase with a DNA template:primer and a deoxynucleoside triphosphate (dNTP), and the crystal structure of the complex was determined at a resolution of 3.2 angstroms. The presence of a dideoxynucleotide at the 3'-primer terminus allows capture of a state in which the substrates are poised for attack on the dNTP. Conformational changes that accompany formation of the catalytic complex produce distinct clusters of the residues that are altered in viruses resistant to nucleoside analog drugs. The positioning of these residues in the neighborhood of the dNTP helps to resolve some long-standing puzzles about the molecular basis of resistance. The resistance mutations are likely to influence binding or reactivity of the inhibitors, relative to normal dNTPs, and the clustering of the mutations correlates with the chemical structure of the drug.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9831551     DOI: 10.1126/science.282.5394.1669

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  519 in total

1.  4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro.

Authors:  E I Kodama; S Kohgo; K Kitano; H Machida; H Gatanaga; S Shigeta; M Matsuoka; H Ohrui; H Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.

Authors:  P L Sharma; C S Crumpacker
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

3.  Analysis of mutations at positions 115 and 116 in the dNTP binding site of HIV-1 reverse transcriptase.

Authors:  P L Boyer; S G Sarafianos; E Arnold; S H Hughes
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

4.  Three telomerases with completely non-telomeric template replacements are catalytically active.

Authors:  T L Ware; H Wang; E H Blackburn
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

5.  Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase.

Authors:  G Tachedjian; H E Aronson; S P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

6.  A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.

Authors:  R A Smith; G J Klarmann; K M Stray; U K von Schwedler; R F Schinazi; B D Preston; T W North
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

7.  Oligomeric structures of poliovirus polymerase are important for function.

Authors:  S D Hobson; E S Rosenblum; O C Richards; K Richmond; K Kirkegaard; S C Schultz
Journal:  EMBO J       Date:  2001-03-01       Impact factor: 11.598

8.  A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity.

Authors:  S Druillennec; C Z Dong; S Escaich; N Gresh; A Bousseau; B P Roques; M C Fournié-Zaluski
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

9.  Template definition by Tetrahymena telomerase reverse transcriptase.

Authors:  M C Miller; J K Liu; K Collins
Journal:  EMBO J       Date:  2000-08-15       Impact factor: 11.598

10.  Crystal structure of mammalian poly(A) polymerase in complex with an analog of ATP.

Authors:  G Martin; W Keller; S Doublié
Journal:  EMBO J       Date:  2000-08-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.